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Aging is an important risk factor for most chronic diseases. Patients with COPD develop
more comorbidities than non-COPD subjects. We hypothesized that the development of
comorbidities characteristically affecting the elderly occur at an earlier age in subjects with
the diagnosis of COPD.
Methods and findings
We included all subjects carrying the diagnosis of COPD (n = 27,617), and a similar number
of age and sex matched individuals without the diagnosis, extracted from the 727,241 rec-
ords of individuals 40 years and older included in the EpiChron Cohort (Aragon, Spain). We
compared the cumulative number of comorbidities, their prevalence and the mortality risk
between both groups. Using network analysis, we explored the connectivity between comor-
bidities and the most influential comorbidities in both groups. We divided the groups into 5
incremental age categories and compared their comorbidity networks. We then selected
those comorbidities known to affect primarily the elderly and compared their prevalence
across the 5 age groups. In addition, we replicated the analysis in the smokers' subgroup to
correct for the confounding effect of cigarette smoking. Subjects with COPD hadmore
comorbidities and died at a younger age compared to controls. Comparison of both cohorts
across 5 incremental age groups showed that the number of comorbidities, the prevalence
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Conclusion
Multimorbidity increases with age but in patients carrying the diagnosis of COPD, these
comorbidities are seen at an earlier age.
Introduction
An increase in life expectancy has led to the aging of populations worldwide[1]. Aging is an
important known risk factors for most chronic diseases, however there is variability in the bur-
den of chronic diseases affecting the old[2,3]. Understanding this variability is key to differen-
tiating pathologic from successful or normal aging[4]. The co-occurrence of chronic diseases
is not a phenomenon of simple chance[5–7], but rather the expression of complex biological
interactions between a susceptible individual and the cumulative effect of environmental expo-
sures, differentially affecting body systems[8].
Chronic Obstructive Pulmonary Disease (COPD) is a representative model of a disease to
help discern pathologic from normal aging[9]: COPD is a disease which affects millions of
people[10], is the third leading cause of death worldwide [11], has a natural history that is rela-
tively well understood[12] and frequently occurs with comorbidities[13,14]. Moreover, in a
big data longitudinal study of the entire Danish population (6.2 million subjects), COPD was
identified as a disease central to the progression of other chronic diseases[15].
COPD is thought to occur due to the slow, progressive and cumulative inflammatory
response to inhaled particles, primarily from cigarette smoke and biomass fuel pollution. Such
low grade persistent inflammation is a phenomenon associated with aging (thus the term
“inflammaging”[16]), leading to the suggestion that COPD may actually represent a disease of
accelerated aging[17,18].
Using network analysis, we tested the hypothesis that patients with a diagnosis of COPD
would not only have an increased number of comorbidities characteristically seen in older
individuals, but these would be detected at a younger age.
Methods
Study design and population
COPD cases and controls were selected from the EpiChron Cohort[19], which links, at the
individual level, clinical and demographic information contained in the electronic medical rec-
ords (EMR) of the 1.3 million inhabitants of the Spanish autonomous community of Aragon.
The Spanish Health System is a single-payer, universal coverage, primary care based model,
managed by the distinct autonomous communities[20]. The single, interconnected EMR sys-
tem was implemented in the Aragon province in 2006 and since then each electronic medical
record has accumulated past and new diagnoses generated from patient’s encounters including
outpatient, hospital or emergency visit and from a proxy methods consisting of linking a spe-
cific diagnosis to every prescription and diagnostic. In this cross-sectional analysis, we
included the anonymized records in the year 2011 of all individuals aged 40 years and older
(n = 727,241), with a physician diagnosis of COPD and an equal number of age and gender
matched group of subjects without the diagnosis. COPD cases were identified as those
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individuals carrying in their EMR any of the following International Classification of Diseases
9th Edition (ICD9) codes 490–492, 494 and 496, in at least two or more encounters[21,22]. We
chose the year 2011 because it provides 5 years of cumulated experience since EMR implemen-
tation (2006) thus the records met the following standards: a percentage of uncoded episodes
less than 20%, a percentage of notes (e.g., prescription, observation, etc.) listed in uncoded epi-
sodes less than 15%, a percentage of prescriptions linked to uncoded episodes less than 10%,
and a percentage of patients with no diagnostic information less than 10%[23].
For each patient, demographics (age and gender), a list of chronic conditions accumulated
over time and cumulatively recorded in the EMR were extracted using an algorithm validated
in previous studies[23,24] and summarized in S1 Fig. In addition, we extracted admission(s)
to acute care hospital for any reason in the prior year (2010) and mortality as of March 30th,
2014. We selected those diseases classified as chronic conditions based on the list proposed by
Salisbury et al[25] totaling 119 diseases included in the final analyses (S1 Table).
Statistical analysis
Data was summarized as mean and standard deviation (SD) or median and interquartile range
(IQR) for continuous variables according to their distribution. Categorical or binomial vari-
ables are presented as proportions. We used two-sample t-tests, Wilcoxon-rank and Chi-
square tests to compare groups, depending on the type of variable and their distribution.
Comorbidities were tabulated as dichotomic variables representing the presence or absence of
the disease. We compared the prevalence and the cumulative number of comorbidities per
individual in the COPD and non-COPD cohorts. Multivariate analysis was used to evaluate
the association between age and the cumulative number of comorbidities using COPD as the
variable of interest. A logistic regression was used to determine the interaction between age,
number of comorbidities and having the diagnosis of COPD is associated with death.
For hypothesis testing comparing both groups a p 0.05 was deemed statistically significant
whereas for Network construction where multiple correlation testing are performed a p 0.01
was chosen as significant as published previously[5]. Finally, bootstrapping with 1000 replica-
tions was conducted to obtain the 95% confidence interval for the network’s statistics.
Network construction and analysis
We constructed the network graphs applying the same methodology used in our previous
work[5]and summarized in S2 Fig of the online supplement. For each network, we deter-
mined: 1. Network density or how many nodes and links hold the network together, 2. The
median and interquartile range of edges for the nodes known as degree, 3. We plotted the degree
distribution to determine if it follows a binomial or exponential distribution suggesting the net-
work’s topology as random or scale free[26].4. Based on the degree distribution, we selected
those nodes at the 75th quartile representing the highly-connected nodes (hubs).
Early aging
We divided both cohorts into 5 incremental age groups (between 40 and 55 years, 56 to 65, 66
to 75, 76 to 85 and above 85 years of age) and constructed their corresponding comorbidities
networks to compare network’s density within and between age groups. Based on the criteria
by Rowe and Kahn[27], we selected those diseases known to affect primarily the elderly and
compared their prevalence at those age groups. The comorbidities included were cataracts,
degenerative joint disease, diabetes mellitus, coronary artery disease, benign prostatic hyper-
trophy, osteoporosis, dementia, depression, hearing loss, skin and lung cancer, chronic renal
failure and atherosclerosis. To discern if cigarette smoking alone and not COPD per se, has an
COPD comorbidity networks and aging
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independent effect on early aging[28], we conducted the same analysis by extracting the sub-
group of confirmed smokers in the non-COPD population and compared the findings to a
similar number of COPD patients matched for age and gender.
This study was approved by the Clinical Research Ethics Committee of Aragon (CEICA).
All analyses were performed using JMP Pro 1 software, version 12.0 (SAS Institute) and
Gephi Graph software V-082 beta[29] to create and analyze the networks.
Results
The age and gender distribution was similar in patients with the diagnosis of COPD and the
controls as shown in Table 1.
Comorbidity burden and outcomes
Excluding COPD in the count of co-existing diseases, patients with the diagnosis of COPD
have an average of two or more comorbidities than the non-COPD patients and this difference
is statistically significant (Table 1). In both groups, females had a higher number of comorbidi-
ties compared to males (p< 0.001).
In both groups the proportion of patients with one or more comorbidity increased with age
(Fig 1 and S3 Fig), however 50% of patients without the diagnosis of COPD at ages 40 to 44
years did not have any chronic disease while this occurred in only 18% of patients carrying the
diagnosis of COPD (p<0.0001). Further, 55.9% of COPD diagnosed individuals aged between
40 and 44 years had two or more comorbidities. A similar proportion (54.7%) of non-COPD
diagnosed individuals with two or more comorbidities occurred in the age group that was on
average 15 years older (age 55 to 59) (Fig 1 Panels A and B, and S2 Table).
There were 5,247 deaths documented in the COPD cohort (19%) compared to 2,911 in the
non-COPD (11%) group, and the difference is statistically significant (p< 0.001). In a logistic
regression model age, number of comorbidities and carrying the diagnosis of COPD were sig-
nificantly correlated with an increased risk for death (p< 0.001).
The odds ratio for 3-year mortality was 2.75 (95% CI 2.66–2.84) for every 10 years of age
increase, 1.09 (95% CI 1.08–1.10) for every increment in the number of comorbidities, and
1.65 (95% CI 1.56–1.74) for carrying the diagnosis of COPD. There were 1,294 patients (4.6%)
Table 1. Subjects' characteristics.
Demographics COPD Controls p-value
Number 27,617 2,7617
Age brackets distribution (n, % of total for the group)
Age 40–55 3,267 (12%) 3,267 (12%)
Age 56 to 65 5,169 (19%) 5,605 (20%)
Age 66 to 75 7,768 (28%) 8,989 (33%)
Age 76 to 85 8,764 (32%) 7,522 (27%)
Age > 85 2,649 (10%) 2,234 (8%)
Gender (n, % of total for the group)
Male n (%) 19378 (70%) 19378 (70%)
Female n (%) 8239 (30%) 8239 (30%)
Number of comorbidities per patient (Mean, SD, 95% CI)
Comorbidities (whole) 4.9 ± 3.4 (4.8–4.9) 3.1± 2.6 (3.1–3.2) <0.001
Male 4.7 ± 3.3 (4.7–4.8) 3.0 ± 2.5 (2.9–3.0) <0.001
Female 5.4 ± 3.6 (5.3–5.4) 3.5 ± 2.7 (3.5–3.6) <0.001
https://doi.org/10.1371/journal.pone.0193143.t001
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with the diagnosis of COPD admitted to a hospital during the year preceding study enrolment
and 107 (0.3%) in the non-COPD cohort.
The prevalence of the 119 selected comorbidities ranged from 0.05 to 56%, and there was a
significantly higher prevalence (p0.05) in ninety-nine of those comorbidities for patients car-
rying the diagnosis of COPD (S4 Fig).
Chronic disease networks
The comorbidity networks are presented in S5 Fig Panel A for the COPD and Panel B for the
non-COPD group. The non-COPD network is comprised of 118 nodes and 1685 links,
whereas in the COPD group there are 119 nodes and 1917 links, resulting in a network with
232 more edges.
Fig 1. Number of comorbidities per individual by age brackets and total mortality. Each band represent the number of comorbidities/patient, and the width the
proportion of individuals with that number of comorbidities at different age brackets (x-axis). Panel A represent those patients carrying the diagnosis of COPD and Panel
B those without COPD. The stacked “Grim Reaper” represents the number of death at 3 years of follow-up (5,247 for COPD and 2,911 in the non-COPD) and their
position is located at the mean age of death; one full “Grim Reaper” represents 1,000 deaths.
https://doi.org/10.1371/journal.pone.0193143.g001
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We plotted the node’s degrees (number of edges or links that a node possesses) distribution
histograms (S6 Fig) and found a right-sided tailed distribution in both networks suggesting a
scale-free architecture. The median number of links per node was 32 (IQR 16–46) for the
COPD diagnosis group and 28 (IQR 13–38) for non-COPD. We identified those comorbidities
that represent hubs by extracting those diseases with highest number of links, namely those in
the upper quartile of the degree distribution histogram (S6 Fig). Thirty diseases (25% of all
nodes) in each network met this definition. Out of those thirty diseases-hubs, twenty-four
were similar in both groups. The six different diseases-hubs were: substance abuse, neuritis,
cirrhosis, anxiety, aortic aneurism and obesity for the COPD network, and cerebrovascular
disease, hyperlipidemia, dementia, eczema, cataracts and paralytic syndromes in the non-
COPD network (S7 Fig and Table 2).
Table 2. Top connected diseases or hubs.
COPD Non-COPD
Rank Disease Prevalence (%) Degree (n) Disease Prevalence (%) Degree (n)
1 Fe Def. Anemia 8 80 Arrhythmia 6.3 68
2 CVS NS 9.9 76 CVS NS 3.6 67
3 GERD 2.4 75 Fe Def. Anemia 3.9 67
4 Resp. Dis. NS 9.5 75 Resp. Dis. NS 1.2 66
5 Arrhythmia 14.4 68 HTN 46 64
6 HTN 55.6 65 CRF 0.8 62
7 Atherosclerosis 2.2 64 CHF 2.9 58
8 CHF 11.4 64 CAD 5.1 57
9 Depression 14.5 62 Diverticulosis 2 57
10 CRF 3.4 62 DM 16.8 56
11 Diverticulosis 4.2 61 DJD 19.7 55
12 CAD 9.7 57 Depression 9 55
13 Valvulopathy 4.9 56 Incontinence 5.2 54
14 Osteoporosis 10.5 55 Dyslipidemia 32.3 53
15 Hemat. Dis. NS 3.9 55 CVA 6.6 53
16 BPH 22.1 55 Atherosclerosis 0.4 52
17 DM 22.1 54 Hypothyroidism 5.5 52
18 Incontinence 9.1 54 GERD 0.5 52
19 Skin Ulcer 3.9 53 Hemat. Dis. NS 1.8 52
20 DJD 24.1 53 BPH 16.2 51
21 Neuritis 3.2 52 Varicose veins 11.1 49
22 Varicose veins 15.1 51 Neuro. Dis. NS 3.5 49
23 Endo. NS 3.2 51 Endo. NS 1.5 47
24 Cirrhosis 1.9 51 Valvulopathy 1.9 46
25 Neuro. Dis. NS 5.5 51 Dementia 3.4 46
26 Substance abuse 4.5 49 Osteoporosis 7.1 45
27 Hypothyroidism 7.9 48 Skin Ulcer 2 44
28 AA 0.7 46 Eczema 7.9 43
29 Obesity 15.9 46 Cataract 11.5 43
30 Anxiety 3.6 46 Paralytic synd. 0.3 42
Twenty-four disease representing network’s hubs are similar in both cohorts, however the ranking and prevalence differ in both groups. The colored cells represent hubs
that differ between the two cohorts. Abbreviations: AA: Aortic Aneurism; BPH: Benign Prostatic Hypertrophy; CAD: Coronary Artery Disease; CHF: Congestive Heart
Failure; CRF: Chronic renal failure; CVA: Cerebrovascular Accident; CVS NS: Other Cerebro Vascular Syndrome; DJD: Degenerative joint disease; DM: Diabetes
Mellitus; Endo. NS: Other endocrinopathy; Fe Def. Anem.: Iron Deficiency Anemia; GERD: Gastro-Esophageal Reflux Disorder; Hemat. Dis. NS: Other Hematology
Disorder; HTN: Hypertension; Neuro. Dis. NS: Neurologic Disorder, other; Resp. Dis. NS: Respiratory disorders, other;
https://doi.org/10.1371/journal.pone.0193143.t002
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Accelerated aging
Both cohorts were divided into five age groups as less than 55 years, 56 to 65 years, 66 to 75
years 76 to 85 and more than 85 years old. We constructed the comorbidities networks for
each subgroup and compared each network’s density (number of nodes, number of edges and
average degree) and diseases prevalence’s and summarized our findings in Fig 2. At every age
category, the COPD Networks include more nodes, have a higher overall diseases prevalence
and are much denser than the non-COPD, except for those older than 85 years old. When
comparing networks density between age categories using the ANOVA test, there was a statis-
tical difference between groups except for those shown in Fig 2 in which cells shaded with sim-
ilar color and connected by brackets. This suggest that the distribution of network’s degree in
the non-COPD aged 66 to 75 and 76 to 85 resemble that of the COPD at age 56 to 65.
Comorbidities of aging
Table 3 shows that except for few instances, the prevalence of diseases related to aging are sig-
nificantly higher in patients carrying the diagnosis of COPD within same age groups.
Comparison were made within the same age categories.
Fig 2. Comparison of network's characteristics by 5-year age groups in both COPD and non-COPD groups. We categorized both groups into five age groups and
built their respective networks to compare the network’s density: total number of nodes (3rd row), total number of connections (4th row), and average degree per node.
Between groups comparisons were calculated for the average degree (last row) and those without statistical difference have similar color and relate to brackets.
https://doi.org/10.1371/journal.pone.0193143.g002
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Fig 3 on the other hand shows that similar prevalence can be observed in COPD patients
aged between 56 and 65 years and those aged 76 to 85 years old in the non-COPD group
(marked with arrows).
Smokers subgroup analysis
There were 1,914 confirmed smokers in the non-COPD group and they were matched by age
and gender with a similar number of randomly selected COPD patients. Their clinical charac-
teristics are shown in S3 Table. In this subgroup analysis, COPD subjects had a higher number
of comorbidities 4.5 ± 3.3 vs 3.3± 2.7 (p<0.001), accumulated the same number of
Table 3. Prevalence comparison of those diseases mostly occurring in elders.
55 years 56±65 years 66±75 years 76±85 years >85 years
Degenerative Joint Disease Non-COPD 4.81% 13.38% 22.02% 27.05% 23.41%
COPD 8.69% 18.48% 25.24% 30.53% 28.95%
Fisher’s exact test < .0001 < .0001 < .0001 < .0001 < .0001
Atherosclerosis Non-COPD 0.00% 0.23% 0.33% 0.73% 1.12%
COPD 0.43% 1.22% 2.09% 3.05% 3.55%
Fisher’s exact test 0.0001 < .0001 < .0001 < .0001 < .0001
Hearing Loss Non-COPD 2.82% 5.42% 7.03% 8.26% 7.34%
COPD 4.81% 7.54% 8.55% 10.98% 11.55%
Fisher’s exact test < .0001 < .0001 0.0003 < .0001 < .0001
Osteoporosis Non-COPD 1.93% 5.85% 7.87% 9.45% 6.58%
COPD 3.95% 9.67% 11.10% 12.44% 12.31%
Fisher’s exact test < .0001 < .0001 < .0001 < .0001 < .0001
Cataract Non-COPD 0.70% 3.76% 11.49% 20.58% 16.83%
COPD 1.93% 6.73% 16.90% 25.22% 21.22%
Fisher’s exact test < .0001 < .0001 < .0001 < .0001 0.0001
Benign Prostatic Hypertrophy Non-COPD 0.61% 6.05% 13.84% 16.46% 13.47%
COPD 1.29% 8.03% 17.83% 22.39% 19.18%
Fisher’s exact test 0.0069 < .0001 < .0001 < .0001 < .0001
Skin CA Non-COPD 0.34% 0.93% 1.45% 2.52% 3.36%
COPD 0.43% 1.08% 1.96% 3.19% 4.15%
Fisher’s exact test 0.6895 0.4396 0.0113 0.0111 0.1534
Lung CA Non-COPD 0.03% 0.27% 0.30% 0.27% 0.09%
COPD 1.19% 2.09% 2.27% 1.32% 0.45%
Fisher’s exact test < .0001 < .0001 < .0001 < .0001 0.0279
Dementia Non-COPD 0.18% 0.25% 1.78% 6.60% 11.32%
COPD 0.43% 0.81% 2.95% 8.28% 14.76%
Fisher’s exact test 0.1148 < .0001 < .0001 < .0001 0.0004
Depression Non-COPD 7.35% 8.05% 9.04% 10.08% 10.03%
COPD 16.19% 14.95% 12.40% 14.98% 15.89%
Fisher’s exact test < .0001 < .0001 < .0001 < .0001 < .0001
Chronic Renal Failure Non-COPD 0.06% 0.20% 0.71% 1.25% 1.92%
COPD 0.52% 1.06% 2.33% 5.33% 7.97%
Fisher’s exact test 0.0007 < .0001 < .0001 < .0001 < .0001
Coronary Artery Disease Non-COPD 0.80% 3.41% 5.51% 7.20% 6.76%
COPD 3.46% 6.81% 10.16% 11.95% 13.82%
Fisher’s exact test < .0001 < .0001 < .0001 < .0001 < .0001
https://doi.org/10.1371/journal.pone.0193143.t003
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comorbidities 15 years earlier than non-COPD smokers S8 Fig, had a higher absolute mortality
(14% vs 7.4% p<0.001, S3 Table). As seen in the analysis of the entire cohort, the prevalence of
age related comorbidities was higher and occurred at a younger age in COPD patients com-
pared to smokers without COPD (S10 Fig).
Fig 3. Prevalence of co-morbidities commonly seen in the elderly between COPD and non-COPD patients at five different age categories. Solid dots ● represent
COPD patients and hollow dots  represent non-COPD patients. The size of the dots is proportional to the number of links (degrees) in their respective networks. Note,
the prevalence (vertical axis) is higher in the COPD group and reach those values seen in non-COPD at an earlier age (horizontal axis). Comorbidities where the
prevalence in COPD is similar to controls 10–20 years earlier are highlighted with a solid arrow # and hollow arrow + in non-COPD. We show in this Fig 2 representative
examples of comorbidities of the elder (osteoporosis and atherosclerosis). For the complete list of comorbidities seen in the elders please refer to S9 Fig.
https://doi.org/10.1371/journal.pone.0193143.g003
COPD comorbidity networks and aging
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Discussion
There are three major findings in this study that compared age and sex matched subjects with
and without the diagnosis of COPD extracted from single-payer, universal coverage population
in Spain. First, the number and type of chronic conditions seen with aging, are registered at a
younger age in subjects carrying the diagnosis of COPD. More notably, the density and comor-
bidity prevalence in the network of individuals carrying the diagnosis of COPD between the
ages of 55 and 65 years resemble those of controls 10 to 20 years older. Second, the network
analysis allowed us to identify thirty highly interconnected diseases or hubs in each group. Inter-
estingly out of those thirty comorbidities, six were unique for each group. For the COPD cohort,
these unique hubs represent mostly behavioral (substance abuse), lifestyle-metabolic (obesity)
and psychiatric (anxiety) disorders which usually affect individuals at earlier stages of their life
and perhaps are in part responsible for an early aging process (S7 Fig and Table 2). In contrast,
for the non-COPD cohort the distinct hubs are diseases characteristically seen at later age
(dementia, cerebrovascular accidents, cataracts, atherosclerosis). Third, in the subgroup analysis
using non-COPD smokers, the same findings were observed, suggesting that pathologic aging
associated with smoking is magnified in those who develop COPD. These three observations
support the hypothesis that having the diagnosis of COPD is associated with early aging.
The process of aging is defined as the progressive decline in body function and homeostasis
that occurs after the reproductive phase of life, leading to an increasing vulnerability to disabil-
ity, multimorbidity and death[30,31]. Our study confirms the known increased vulnerability
for comorbidities that comes with age, but emphasizes that carrying the diagnosis of COPD
enhances this risk. Previous studies have suggested the presence of early aging in patients with
COPD as manifested by the relationship between severity of airflow limitation and increased
number and depth of facial wrinkles, stiffer peripheral arteries[32] and osteoporosis[33]. As
shown in Fig 3 and S9 Fig, we expand on these observations by demonstrating that for diseases
characteristically occurring in the elderly, the prevalence was higher in subjects with COPD
compared with those without the disease. Importantly, a similar prevalence of those diseases
was reached one or two decades earlier in patients with the diagnosis of COPD. The conse-
quences were not menial since those patients carrying the diagnosis of COPD had more deaths
and on average died at a younger age than patients without that diagnosis. Ito and Barnes pro-
posed that the mechanisms leading to premature aging in COPD include cellular senescence,
stem cell exhaustion, increased oxidative stress, alteration in the extracellular matrix, reduction in
endogenous antiaging molecules and an alteration in protective pathways such as autophagy[17].
More recently, Rutten et al demonstrated that a panel of molecular markers of aging were distinc-
tively altered in patients with COPD compared with non-obstructed current smokers and healthy
control[34]. This suggests that patients with COPD have an enhanced pathobiological reaction to
the exposure to cigarette smoke. Our findings, comparing the subgroup of smokers without
COPD and those with COPD, provide evidence for this differential response to cigarette smoke
and support the argument of differential susceptibility to accelerated aging among smokers.
Using diseases networks, our results also suggest the possibility that organ systems, and not just
the lungs, could be affected differentially by such aging related mechanisms and the phenotypic
expression is the burden of comorbidities that co-occur beyond simple chance.
In addition, the network analysis allows us to better visualize the complex interactions
between individual components and the identification of more influential nodes. This aggre-
gate of multiple diseases and their statistical correlations provide the basis for the comorbidity
network shown in Fig 3. It represents a complex system of diseases interacting to form an elab-
orate mesh of nodes and links, but this integrative methodology helps us discover two main
emerging properties of the system hardly evident if we study individual or small groups of
COPD comorbidity networks and aging
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diseases separately. First, the comorbidity networks have features of scale-free networks, allow-
ing us to identify hubs represented by those 25% of diseases holding more than 47% of all con-
nections (S7 Fig and Table 2). Second, not surprisingly, 24 of the 30 diseases representing hubs
were shared in both COPD and non-COPD networks. We identified, however, six other
comorbidities unique to each group. Interestingly, for COPD, those unique hubs represent
mostly behavioral (substance abuse), lifestyle (obesity) and psychiatric (anxiety) disorders
which usually affect individuals at earlier stages of their life, and perhaps are in part responsible
for the early aging process. As suggested in previous studies, those hubs could potentially be
targeted for intervention as the basis of network perturbation experiments. This benefit of
treatment cross-effect in multimorbidity is in dire need of testing[5,35–41].
The primary strength of this study is its large, real life, representative, primary care based
population that enabled us to examine with precision the associations of a diverse and large
group of chronic diseases affecting individuals at different age groups. However, as is true of
population based studies, there are several limitations. First, the diagnosis of COPD could not
be confirmed by spirometry leading to mis or underdiagnoses. To mitigate this limitation, we
used the EpiChron database which is a clinical database rather than just an administrative one,
we identified a large cohort of cases extracted from a broad primary and secondary interlinked
practices, and used a validated algorithm to mine those cases and matched them. Mining elec-
tronic health records is becoming an increasingly relevant source of discovery[6,15,21,42] by
providing large datasets, and in our study the unique opportunity to include 119 different
chronic diseases. Arguably, a daunting and expensive task for a prospective study aimed to
objectively confirm each of those conditions. Second, it is possible that the prevalence of cur-
rent smokers was underestimated, as published prevalence estimate in Spain varies between
25–35% for adults 40 years and older[43], while in our sample smoking status was reported at
a prevalence of 21% for COPD patients and 7% for non-COPD. To address this limitation, we
conducted the same analysis on those confirmed smokers that had COPD and compared them
with that of non-COPD subjects. The results were similar to those we observed in the whole
cohort, indicating that the phenomenon of accelerated aging is more marked in susceptible
smokers who develop COPD than in smokers in general. Third, we selected COPD as the
index disease, nonetheless it is possible that our findings may not be exclusive of COPD, a
point that will require future studies using other relevant chronic diseases. Finally, the study is
cross-sectional by design limiting the possibility of exploring the evolution of disease networks
over time. We included representative samples in all age categories, compared them with a
control group and highlighted the within and the between age categories comparisons.
In conclusion, using comorbidities networks analysis, this study supports the concept that
individuals carrying the diagnosis of COPD are more predisposed at an earlier age to diseases
characteristically seen in the elderly. In addition, it highlights some influential comorbidities
that could act as potential drivers of this process. Identifying these drivers should help clini-
cians screen for those diseases earlier in the clinical course of COPD patients. For the research-
ers, deciphering the pathobiological mechanisms underlying these interlinked diseases could
result in interventions capable of preventing or reversing them.
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non-COPD patients at five different age categories. Solid dots ● represent COPD patients
and hollow dots  represent non-COPD patients. The size of the dots is proportional to the
number of links (degrees) in their respective networks. Note, the prevalence (vertical axis) is
higher in the COPD group and reach those values seen in non-COPD at an earlier age (hori-
zontal axis). Comorbidities where the prevalence in COPD is similar to controls 10–20 years
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Zulueta, Ciro Casanova, Victor M. Pinto-Plata, Carlos Cabrera-Lopez, Francesca Polverino,
Jonás Carmona Pı́réz, Alexandra Prados-Torres, Jose M. Marin.
References
1. Beard JR, Officer A, de Carvalho IA, SadanaR, Pot AM, Michel J-P, et al. TheWorld report on ageing
and health: a policy framework for healthy ageing. Lancet. 2016; 387: 2145±2154. https://doi.org/10.
1016/S0140-6736(15)00516-4 PMID: 26520231
2. Prados-Torres A, CalderoÂn-Larrañaga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. Mul-
timorbidity patterns: a systematic review. Journal of Clinical Epidemiology. 2014; 67: 254±266. https://
doi.org/10.1016/j.jclinepi.2013.09.021 PMID: 24472295
3. Barnett K, Mercer SW, NorburyM, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and
implications for health care, research, andmedical education: a cross-sectional study. Lancet. 2012;
380: 37±43. https://doi.org/10.1016/S0140-6736(12)60240-2 PMID: 22579043
4. Rowe JW, Kahn RL. Successful aging. Gerontologist. 1997; 37: 433±440. https://doi.org/10.1093/
geront/37.4.433 PMID: 9279031
5. DivoMJ, CasanovaC, Marin JM, Pinto-Plata VM, de Torres JP, Zulueta JJ, et al. Chronic obstructive
pulmonary disease comorbidities network. EuropeanRespiratory Journal. 2015; 46: 640±650. https://
doi.org/10.1183/09031936.00171614 PMID: 26160874
6. HidalgoCA, BlummN, BarabaÂsi A-L, Christakis NA. A Dynamic Network Approach for the Study of
Human Phenotypes. Meyers LA, editor. PLoSComput Biol. 2009; 5: e1000353. https://doi.org/10.1371/
journal.pcbi.1000353PMID: 19360091
7. Gomez-Cabrero D, Menche J, VargasC, Cano I, Maier D, BarabaÂsi A-L, et al. From comorbidities of
chronic obstructive pulmonary disease to identification of sharedmolecularmechanisms by data integra-
tion. BMCBioinformatics. 2016; 17: 441. https://doi.org/10.1186/s12859-016-1291-3 PMID: 28185567
8. Loscalzo J, Kohane I, BarabaÂsi A-L. Human disease classification in the postgenomic era: a complex
systems approach to human pathobiology. Mol Syst Biol. 2007; 3: 124. https://doi.org/10.1038/
msb4100163 PMID: 17625512
9. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, et al. Geroscience: Linking Aging
to Chronic Disease. Cell. Elsevier Inc; 2014; 159: 709±713. https://doi.org/10.1016/j.cell.2014.10.039
PMID: 25417146
10. ManninoDM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. The Lancet.
2007; 370: 765±773. https://doi.org/10.1016/S0140-6736(07)61380-4
11. LozanoR, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn
SY, AlMazroaMA, et al. Global and regionalmortality from 235 causes of death for 20 age groups in
COPD comorbidity networks and aging
PLOSONE | https://doi.org/10.1371/journal.pone.0193143 February 22, 2018 14 / 16
1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. Else-
vier Ltd; 2012; 380: 2095±2128. https://doi.org/10.1016/S0140-6736(12)61728-0
12. Lange P, Celli B, AgustõÂA, Boje JensenG, DivoMJ, Faner R, et al. Lung-Function Trajectories Leading
to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015; 373: 111±122. https://doi.org/10.1056/
NEJMoa1411532PMID: 26154786
13. Baty F, Putora PM, Isenring B, Blum T, BrutscheM. Comorbidities and Burden of COPD: A Population
Based Case-Control Study. PLoSONE. Public Library of Science; 2013; 8: e63285. https://doi.org/10.
1371/journal.pone.0063285PMID: 23691009
14. DivoMJ, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of
mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186:
155±161. https://doi.org/10.1164/rccm.201201-0034OC PMID: 22561964
15. Jensen AB, Moseley PL, Oprea TI, Ellesøe SG, Eriksson R, Schmock H, et al. Temporal disease trajec-
tories condensed from population-wide registry data covering 6.2 million patients. Nat Commun. Nature
PublishingGroup; 2014; 5: 1769. https://doi.org/10.1038/ncomms5022 PMID: 24959948
16. Franceschi C, Capri M, Monti D, Giunta S, OLIVIERI F, Sevini F, et al. Inflammaging and anti-inflamma-
ging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing
Dev. 2007; 128: 92±105. https://doi.org/10.1016/j.mad.2006.11.016 PMID: 17116321
17. Ito K, Barnes PJ. COPD as a Disease of Accelerated Lung Aging. CHEST. AmericanCollege of Chest
Physicians; 2009; 135: 173±180. https://doi.org/10.1378/chest.08-1419PMID: 19136405
18. Vogelmeier C, Bals R. Chronic obstructive pulmonary disease and premature aging. Am J Respir Crit
Care Med. 2007; 175: 1217±1218. https://doi.org/10.1164/rccm.200703-513EDPMID: 17545454
19. Prados-Torres A, Poblador-Plou B, Gimeno-Feliu LA, Gonzalez-Rubio F, Laguna-Berna C, Marta-
Moreno J, et al. The Epidemiology of Chronic Diseases andMultimorbidity (EpiChron) Cohort Study. Int
J Epidemiol. 2018; Forthcomming https://doi.org/10.1093/ije/dyx259PMID: 29346556
20. GarcõÂa-Armesto S, Begoña AbadõÂa-Taira M, DuraÂn A, HernaÂndez-QuevedoC, Bernal-Delgado E.
Spain: Health system review. Health Syst Transit. 2010; 12: 1±295± xix±xx.
21. Almoguera B, Vazquez L, Mentch F. Identification of Four Novel Loci in Asthma in European and African
American Populations. American Journal of . . .. 2016.
22. CookeCR. The validity of using ICD-9 codes and pharmacyrecords to identify patients with chronicob-
structive pulmonary disease. BioMedCentral Ltd; 2011;: 1±10. https://doi.org/10.1186/1472-6963-11-
37 PMID: 21324188
23. Prados-Torres A, Poblador-Plou B, Calder o n-Larra n aga A, Gimeno-Feliu LAES, Gonz a lez-Rubio F,
Poncel-Falc o A, et al. Multimorbidity patterns in primary care: interactions among chronic diseases
using factor analysis. PLoSONE. 2012;7. https://doi.org/10.1371/journal.pone.0032190 PMID:
22393389
24. Poblador-Plou B, van den Akker M, Vos R, CalderoÂn-Larrañaga A, Metsemakers J, Prados-Torres A.
Similar Multimorbidity Patterns in Primary Care Patients from Two EuropeanRegions: Results of a Fac-
tor Analysis. PLoSONE. Public Library of Science; 2014; 9: e100375. https://doi.org/10.1371/journal.
pone.0100375 PMID: 24956475
25. Huntley AL, JohnsonR, Purdy S, Valderas JM, Salisbury C. Measures of Multimorbidity andMorbidity
Burden for Use in Primary Care and Community Settings: A Systematic Review andGuide. The Annals
of Family Medicine. 2012; 10: 134±141. https://doi.org/10.1370/afm.1363 PMID: 22412005
26. BarabaÂsi A-L, GulbahceN, Loscalzo J. Network medicine: a network-based approach to human dis-
ease: Abstract: Nature ReviewsGenetics. 2011; 12: 56±68. https://doi.org/10.1038/nrg2918PMID:
21164525
27. Rowe JW, Kahn RL. Human aging: usual and successful. Science. 1987; 237: 143±149. PMID:
3299702
28. Jha P, Peto R. Global Effects of Smoking, of Quitting, and of Taxing Tobacco. N Engl J Med. 2014; 370:
60±68. https://doi.org/10.1056/NEJMra1308383PMID: 24382066
29. BastianM, Heymann S, JacomyM. Gephi: An Open Source Software for Exploring andManipulating
Networks. Proceedings of the Third International ICWSMConference. 2009.
30. Fried LP, Ferrucci L, Darer J, Williamson JD, AndersonG. Untangling the Concepts of Disability, Frailty,
and Comorbidity: Implications for Improved Targeting and Care. The Journals of Gerontology Series A:
Biological Sciences andMedical Sciences. 2004; 59: M255±M263. https://doi.org/10.1093/gerona/59.
3.M255
31. LoÂpez-OtõÂn C, BlascoMA, Partridge L, SerranoM, Kroemer G. The hallmarks of aging. Cell. 2013; 153:
1194±1217. https://doi.org/10.1016/j.cell.2013.05.039 PMID: 23746838
COPD comorbidity networks and aging
PLOSONE | https://doi.org/10.1371/journal.pone.0193143 February 22, 2018 15 / 16
32. Patel BD, LooWJ, Tasker AD, Screaton NJ, Burrows NP, Silverman EK, et al. Smoking related COPD
and facial wrinkling: is there a common susceptibility? Thorax. 2006; 61: 568±571. https://doi.org/10.
1136/thx.2005.053827 PMID: 16774949
33. Sabit R, Bolton CE, Edwards PH, Pettit RJ, EvansWD, McEniery CM, et al. Arterial stiffness and osteo-
porosis in chronic obstructive pulmonary disease. Am J Respir Crit CareMed. 2007; 175: 1259±1265.
https://doi.org/10.1164/rccm.200701-067OCPMID: 17363772
34. PhDEPAR, MSc PG, PhD EFMWM, PhD FMEFM, PhDGJH, PhD LEVM, et al. VariousMechanistic
Pathways Representing the Aging Process Are Altered in COPD. CHEST. Elsevier Inc; 2016; 149: 53±
61. https://doi.org/10.1378/chest.15-0645PMID: 26066545
35. Vanfleteren LEGW. Does COPD stand for ªCOmorbidity with Pulmonary Disease?º 2014;: 1±4. https://
doi.org/10.1183/09031936.00148014 PMID: 25552731
36. Vanfleteren L, Spruit MA, Franssen F. Tailoring the approach to multimorbidity in adults with respiratory
disease: the NICE guideline. 2017.
37. MacneeW, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Euro-
pean Respiratory Journal. EuropeanRespiratory Society; 2014; 44: 1332±1352. https://doi.org/10.
1183/09031936.00134014PMID: 25323246
38. Carraro S, ScheltemaN, Bont L, Baraldi E. Early-life origins of chronic respiratory diseases: under-
standing and promoting healthy ageing. EuropeanRespiratory Journal. EuropeanRespiratory Society;
2014; 44: 1682±1696. https://doi.org/10.1183/09031936.00084114PMID: 25323240
39. AgustõÂA, AntoÂJM, Auffray C, BarbeÂF, Barreiro E, Dorca J, et al. Personalized respiratorymedicine:
exploring the horizon, addressing the issues. Summary of a BRN-AJRCCMworkshop held in Barcelona
on June 12, 2014. 2015. pp. 391±401. https://doi.org/10.1164/rccm.201410-1935PPPMID: 25531178
40. Faner R, AgustõÂA. Multilevel, Dynamic Chronic Obstructive Pulmonary DiseaseHeterogeneity. A Chal-
lenge for Personalized Medicine. Ann Am Thorac Soc. 2016; 13: S466±S470. https://doi.org/10.1513/
AnnalsATS.201605-372AWPMID: 28005422
41. DivoM, CabreraC. Which Are TheMost Relevant Comorbidities In COPD? BRNReviews. 2016; 2:
215±228. Available: http://www.brnreviews.com/files/brnr_v2_n4_215-228.pdf
42. Ortega VE, Torgerson DG. On a CollisionCourse: The Electronic Medical Record and Genetic Studies
of Asthma. Am J Respir Crit CareMed. 2017; 195: 412±414. https://doi.org/10.1164/rccm.201609-
1941EDPMID: 28199158
43. Regidor E, Gutierrez-Fisac JL, Calle ME, Navarro P, DomõÂnguez V. Trends in cigarette smoking in
Spain by social class. Prev Med. 2001; 33: 241±248. https://doi.org/10.1006/pmed.2001.0872 PMID:
11570827
COPD comorbidity networks and aging
PLOSONE | https://doi.org/10.1371/journal.pone.0193143 February 22, 2018 16 / 16
